Vanguard Group Inc. increased its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 18.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,006,210 shares of the company's stock after acquiring an additional 156,768 shares during the quarter. Vanguard Group Inc. owned about 3.66% of GeneDx worth $77,337,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the business. MCF Advisors LLC grew its holdings in GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company's stock worth $27,000 after acquiring an additional 182 shares during the period. Global Retirement Partners LLC acquired a new position in GeneDx in the fourth quarter valued at about $28,000. KLP Kapitalforvaltning AS acquired a new position in GeneDx in the fourth quarter valued at about $200,000. Evolution Wealth Advisors LLC bought a new position in GeneDx during the fourth quarter worth about $202,000. Finally, Victory Capital Management Inc. acquired a new position in shares of GeneDx during the 4th quarter worth about $209,000. Institutional investors own 61.72% of the company's stock.
Analyst Ratings Changes
WGS has been the topic of several research analyst reports. TD Cowen raised their price objective on GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a research note on Tuesday, January 7th. The Goldman Sachs Group increased their price target on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research report on Wednesday, February 19th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, GeneDx currently has a consensus rating of "Moderate Buy" and a consensus target price of $72.33.
View Our Latest Stock Report on WGS
Insider Activity
In other GeneDx news, CEO Katherine Stueland sold 46,594 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $89.62, for a total transaction of $4,175,754.28. Following the sale, the chief executive officer now directly owns 1,720 shares of the company's stock, valued at $154,146.40. The trade was a 96.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Kevin Feeley sold 922 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $94.72, for a total transaction of $87,331.84. Following the transaction, the chief financial officer now directly owns 5,446 shares of the company's stock, valued at $515,845.12. The trade was a 14.48 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 138,780 shares of company stock worth $12,907,437. Corporate insiders own 27.30% of the company's stock.
GeneDx Stock Performance
Shares of GeneDx stock traded down $2.11 during trading on Wednesday, reaching $100.11. The company's stock had a trading volume of 103,697 shares, compared to its average volume of 674,026. GeneDx Holdings Corp. has a 52 week low of $8.63 and a 52 week high of $115.60. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The business's 50-day moving average price is $91.91 and its 200-day moving average price is $78.94. The firm has a market cap of $2.81 billion, a PE ratio of -51.08 and a beta of 1.93.
GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million during the quarter, compared to analysts' expectations of $82.24 million. Equities analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.
About GeneDx
(
Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Featured Stories
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
